Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IBI3014 in unresectable locally advanced or metastatic solid tumors
CTR20251154Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3014 in Nonhematologic neoplasms, sponsored by InnoCare Pharma. Started Apr 2025; status: active.
02
Drugs
IBI3014
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251154.